Alnylam Pharmaceuticals, Inc.
Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof
Last updated:
Abstract:
The invention relates to polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such polynucleotide agents to inhibit expression of PD-L1 and to treat subjects having a PD-L1-associated disorder.
Status:
Grant
Type:
Utility
Filling date:
9 Dec 2016
Issue date:
20 Apr 2021